Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJRegenmed
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjneurology logo
VJDementia
Logo
  • Diseases
    Alzheimer's Disease
    Dementia
    Dementia with Lewy Bodies
    Frontotemporal Dementia
    Vascular Dementia
    Mild Cognitive Impairment
    View all Diseases
  • Topics
    Diagnostics
    Biology
    Biomarkers
    Treatment
    Clinical Care
    Prevention
    View all Topics
  • Conferences
    AAIC 2023
    BNA 2023
    AD/PD 2023
    ARUK 2023
    CTAD 2022
    AAIC 2022
    View all Conferences
  • Features
  • Podcasts
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

Potential new therapies for Alzheimer’s disease to look out for in 2022: anti-amyloid-β antibodies

The number of individuals worldwide with Alzheimer’s disease is growing at a rapid rate. Therefore, new treatments are urgently needed….

Read More

The Phase II/III GAIN Trial: atuzaginstat for mild-moderate Alzheimer’s disease

Atuzaginstat, a novel small-molecule bacterial protease lysine gingipain inhibitor, is currently under investigation as a first-in-class treatment to slow or…

Read More

Novel antibody donanemab receives FDA breakthrough designation for Alzheimer’s disease

A hallmark feature of Alzheimer’s disease (AD) is the aggregation of amyloid-β (Aβ). Although many trials have been conducted aiming…

Read More

Aducanumab receives accelerated FDA approval for early Alzheimer’s disease

The Food and Drug Administration (FDA) has granted accelerated approval to aducanumab for the treatment of early Alzheimer’s disease (AD)….

Read More

Could retinal changes help predict Alzheimer’s disease onset?

Alzheimer’s disease (AD) is a degenerative condition that affects the brain due to the accumulation of protein aggregates, mainly amyloid…

Read More

Medical management issues in dementia: new EAN guideline

The detrimental effects of dementia negatively impact many peoples’ lives – with a markedly decreased quality of life and increased…

Read More

Alzheimer’s disease: uncovering the mechanisms of protective mutations

Alzheimer’s disease (AD) is a progressive disease affecting millions worldwide and is well known for its characteristic symptom of memory…

Read More

The use of rotigotine as a drug to improve cognitive function in individuals with Alzheimer’s disease

Alzheimer’s disease (AD) is a progressive brain disorder that causes a degeneration of memory and cognitive skills majorly caused by…

Read More
  • Previous
  • 1
  • 2
  • 3
  • Next
Journal Pages
  • Diseases
  • Topics
  • Medicines
  • Trials
  • Conferences
  • Features
Newsletter

Receive the latest news and videos from VJDementia via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJDementia logo
The content of VJDementia is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy